Reference/ treatment | Patients | Prior treatment | Efficacy response % | Survival analysis | |||||||||||
Radiation therapy % | Chemotherapy % | ||||||||||||||
Total No. | CR | PR | SD | PFS (%) | OS (%) | ||||||||||
Median-months | 6 months | Median-months | 6 months | 1 year | 2 years | 5 years | 10 years | ||||||||
Lashford et al., 2002, Temozolomide [21] | 43 | All | 63 | 0 | 9 | 14 | 4.8 | ||||||||
Nicholson et al., 2007Temozolomide [22] | 23 | 84 | All | 0 | 4 | 30 | |||||||||
Warren et al., 201206-benzylguanine and temozolomide [23] | 41 | All | 1 median chemo therapy regimen | 0 | 2 | 12 | 16* 0** | ||||||||
Burzynski et al., 2014ANP(Study eligible) | 41 | 90.2 | 80.5 | 2.4 | 9.8 | 17.1 | 2.5 | 22 | 4.8 | 46.3 | 12.2 | 4.8 | 4.8 | 4.8 | |
Burzynski et al., 2014ANP (DIPG) | 12 | 91.6 | 75.0 | 8.3 | 25 | 33.3 | 4.8 | 41.7 | 6.1 | 58.3 | 25.0 | 8.3 | 8.3 | 8.5 | |
Burzynski et al., 2014ANP (AA) | 8 | 87.5 | 75 | 0 | 12.5 | 12.5 | 3.7 | 25.0 | 4.7 | 37.5 | 12.5 | 12.5 | 12.5 | 12.5 |